WO2016075542A1 - Methods for extended storage of activated leukocyte compositions - Google Patents
Methods for extended storage of activated leukocyte compositions Download PDFInfo
- Publication number
- WO2016075542A1 WO2016075542A1 PCT/IB2015/002285 IB2015002285W WO2016075542A1 WO 2016075542 A1 WO2016075542 A1 WO 2016075542A1 IB 2015002285 W IB2015002285 W IB 2015002285W WO 2016075542 A1 WO2016075542 A1 WO 2016075542A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alc
- activated leukocyte
- leukocyte
- leukocytes
- cells
- Prior art date
Links
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 145
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 238000003860 storage Methods 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims description 44
- 230000000694 effects Effects 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 44
- 210000002966 serum Anatomy 0.000 claims description 15
- 230000002035 prolonged effect Effects 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 abstract description 2
- 206010052428 Wound Diseases 0.000 description 52
- 208000027418 Wounds and injury Diseases 0.000 description 52
- 238000004458 analytical method Methods 0.000 description 27
- 239000012467 final product Substances 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 25
- 210000004698 lymphocyte Anatomy 0.000 description 24
- 210000002381 plasma Anatomy 0.000 description 21
- 102000004890 Interleukin-8 Human genes 0.000 description 19
- 108090001007 Interleukin-8 Proteins 0.000 description 19
- 230000004913 activation Effects 0.000 description 18
- 210000003714 granulocyte Anatomy 0.000 description 17
- 230000035899 viability Effects 0.000 description 14
- 238000011534 incubation Methods 0.000 description 13
- 238000012417 linear regression Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 10
- 102100033467 L-selectin Human genes 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 230000029663 wound healing Effects 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000006354 HLA-DR Antigens Human genes 0.000 description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 description 8
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 8
- 102100025136 Macrosialin Human genes 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- 206010054880 Vascular insufficiency Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000023577 vascular insufficiency disease Diseases 0.000 description 5
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000000516 activation analysis Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000005305 organ development Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- -1 sterile Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010023728 Alloderm Proteins 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 108010001781 Apligraf Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 208000020322 Gaucher disease type I Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- HPNSNYBUADCFDR-UHFFFAOYSA-N chromafenozide Chemical compound CC1=CC(C)=CC(C(=O)N(NC(=O)C=2C(=C3CCCOC3=CC=2)C)C(C)(C)C)=C1 HPNSNYBUADCFDR-UHFFFAOYSA-N 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001206 effect on leukocytes Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000002639 hyperbaric oxygen therapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 238000009581 negative-pressure wound therapy Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Definitions
- the wound healing process involves participation of white blood cells, also known as leukocytes.
- Leukocytes include lymphocytes, granulocytes and monocytes.
- Three common types of lymphocytes are T-cells, B-cells and natural killer cells.
- T-cells and B-cells play important roles in the recognition of antigens in the body (Parkin, 2001 ).
- Natural killer (NK) cells identify infected cells by alterations in the levels of the major histocompatability complex (MHC), and destroy the infected cells (Moretta, 2008).
- MHC major histocompatability complex
- MHC major histocompatability complex
- the participation of lymphocytes in the healing process is largely associated with their production of cytokines and growth factors (Keen, 2008).
- gamma-delta- T cells A new class of gamma-delta- T cells has been described in the skin (Jameson, 2002; Havran, 2005).
- granulocytes are neutrophils, basophils, and eosinophils.
- Monocytes differentiate into macrophages, which are responsible for destruction of tissue debris or invading foreign substances. Macrophages also produce molecules that control inflammation and repair (Riches, 1996). All of these cells types contribute to the process of wound healing in mammals.
- the process of wound healing occurs in three overlapping phases. (Li, 2007; Broughton, 2006; Tsirogianni, 2006; Singer, 1999; Martin, 1997).
- the first phase is the inflammatory phase. It is characterized by recruitment of neutrophils, followed by monocytes to the wound site, where they kill and phagocytize bacteria (Agaiby, 1999).
- the second wound healing phase which is known as the proliferative phase, involves formation of new granulation tissue. Fibroblasts proliferate and migrate into the wound space and synthesize collagen and other components of extracellular matrix (Greiling, 1997). At the same time, angiogenesis occurs, providing nutrients and oxygen to the metabolically active new granulation tissue (Tonnesen,
- Keratinocytes from the intact epidermis start to migrate over the provisional matrix and begin to proliferate, leading the way for new epithelial tissue (Kim, 1992).
- Remodeling is the third and final phase in wound healing. It is characterized by fibroblast differentiation into myofibroblasts, which contract and bring the wound edges closer together (Tomasek, 2002). Remodeling of the collagen fibers by degradation and re-synthesis allows the wound to gain strength by re-orientation of the collagen fibers (a process tightly controlled by growth factors) (Werner, 2003).
- ALC Activated leukocyte compositions
- the ALC Maintained at room temperature, the ALC has a commercially useful shelf life of up to 50 hours measured from the time of blood donation, or 27 hours after completing production of the ALC. This relatively short shelf life places a logistical constraint on the manufacturing, shipping and distribution, and therapeutic use of the ALC. Such problems are particularly acute in the case of large-scale ALC production required to address market demands, which implies a large number of participating donors and relatively long-term storage before the product is administered to patients.
- a suitable storage solution is also critical since the ultimate therapeutic efficacy for the ALC depends on the activity profile of the leukocytes, which may change over time as the various subsets of cells in the ALC respond to storage conditions in different ways. Therefore, it is desirable to provide a storage solution that allows the ALC to be stored for extended periods of time before its therapeutic use and, at the same time, provides a good retention of leukocyte stability and activity over time.
- the present embodiments described are on the discovery that storing an activated leukocyte composition (ALC) under at temperatures below room temperature provides for good retention of leukocyte stability and activity of the ALC for extended periods of time.
- ALC activated leukocyte composition
- a method for the storing an activated leukocyte composition comprising providing the activated leukocyte composition, and maintaining the activated leukocyte composition at a temperature ranging from above 0° C to below about 10° C.
- the temperature ranges from about 2° C to about 8° C.
- the temperature ranges from about 4° C to about 6° C.
- the temperature is about 5° C.
- the activated leukocyte composition is maintained at a temperature ranging from 2° C to about 8° C for about 1 , 2, 3, 4, 5, 6, or 7 days. In other disclosed methods, the activated leukocyte composition is maintained at a temperature ranging from about 4° C to about 6° C for about 1 , 2, 3, 4, 5, 6, or 7 days. On other disclosed methods, the activated leukocyte composition is maintained at a temperature of about 5° C for about 1 , 2, 3, 4, 5, 6, or 7 days.
- an activated leukocyte composition stored at a temperature ranging from above 0° C to below about 10° C.
- the composition comprises serum.
- at least 85% of cells in the activated leukocyte composition remain viable after seven days of storage.
- at least 90% of cells in the activated leukocyte composition remain viable after seven days of storage.
- Also disclosed is a method for prolonging the activity of leukocytes in an activated leukocyte composition comprising providing the activated leukocyte composition, and
- the temperature ranges from about 2° C to about 8° C. In other embodiments, the temperature ranges from about 4° C to about 6° C. In another embodiment, wherein the temperature is about5° C.
- the activated leukocyte composition is maintained at a temperature ranging from 2° C to about 8° C for about 1 , 2, 3, 4, 5, 6, or 7 days. In other disclosed embodiments, the activated leukocyte composition is maintained at a temperature ranging from 4° C to about 6° C for about 1 , 2, 3. 4, 5, 6, or 7 days. In additional disclosed methods, the activated leukocyte composition is maintained at a temperature of about 5° C for about 1 , 2, 3, 4, 5, 6, or 7 days.
- activated leukocyte compositions comprising leukocytes having prolonged activity made according to the methods disclosed herein.
- FIG. 1 illustrates the leukocyte (or white blood cell, hereinafter WBC) viability of three final product (FP) batches before and after storage at 2-8° C.
- WBCs viability was measured at time "0" (i.e., before storage) and after storage and plotted against post-production days.
- Linear regression analysis for WBC viability was performed.
- the dotted lines represent the 95% confidence limits of the linear regression analysis for the plotted data line for each FP batch.
- FIG. 2 illustrates the leukocyte (WBC) concentration of three FP batches before and after storage at 2-8° C.
- WBCs concentration was measured with a Cell Dyn Analyzer at time "0" (i.e., before storage) and after storage and plotted against post-production days. Linear regression analysis for WBCs concentration was performed. The dotted lines represent the 95% confidence limits of the linear regression analysis for the plotted data line for each FP batch.
- FIG. 3 illustrates the lymphocyte percentage of the three FP batches before and after storage at 2- 8° C. Lymphocyte percentage was measured with a Cell Dyn Analyzer at time "0" (i.e., before storage) and after storage and plotted against post-production days. Linear regression analysis for lymphocyte percentage was performed. The dotted lines represent the 95% confidence limits of the linear regression analysis for the plotted data line for each FP batch.
- FIG. 4 illustrates the granulocyte activation (potency) of the three FP batches before and after storage at 2-8° C.
- Leukocytes were stained with the antibody against activated form of CD 1 l b (clone CBRMl/15) conjugated to phycoerythrin (PE) at time "0" (i.e., before storage) and after storage.
- Mean Florescence Intensity (MFI) of the CD 1 lb staining was plotted against post-production days. Linear regression analysis for MFI was performed. The dotted lines represent the 95% confidence limits of the linear regression analysis for the plotted data line for each FP batch.
- FIG 5 provides an analysis of CD1 l b expression of ALCs before and after storage.
- FIG. 6 provides an analysis of IL-8 content of ALCs before and after storage.
- FIG. 7 provides an analysis of CD62L expression of ALCs before and after storage.
- FIG. 8 provides an analysis of CD68 expression of ALCs before and after storage.
- FIG. 9 provides an analysis of HLA-DR expression of ALCs before and after storage.
- FIG. 10 shows the effect on WBC concentration when activated leukocytes are stored at room temperature.
- FIG. 1 1 shows effect on leukocyte percentage when activated leikocytes are stored at room temperature.
- Blood is defined herein as whole blood or any of its constituent parts (e.g., plasma, leukocytes, platelets or red blood cells).
- the amounts of platelets and red blood cells that may be present in the ALC may be lower than that in whole blood.
- the starting materials for producing the ALCs may be obtained from several sources.
- Whole blood or one or more components thereof e.g., leukocytes and plasma
- the blood sample is collected from the patient who will ultimately be treated with the ALC, which is referred to herein as an autologous blood sample or source.
- the source(s) i.e., the blood or its components
- these starting materials may be conveniently obtained from a blood bank.
- the samples may be screened by the blood bank for blood type (ABO, Rh), irregular antibodies to red cell antigens, and transfusion- transmittable diseases.
- screening can be conducted with antibodies using an Abbott PRISM instrument against: Hepatitis B, C, HIV 1/2, HTLV and Syphilis (-HCV; HbsAg; anti-HIV 1/2 0+; and anti-HTLV I/II).
- the samples can also be screened for HIV, HCV and HBV by molecular methods (NAT-Nucleic Acid Testing).
- Molecular screening can be accomplished using commercially available instrumentation, e.g., the TIGRIS system of Chiron.
- the samples can be obtained from donors with the same blood type as the intended ALC recipient.
- plasma samples can be obtained from donors with AB+ blood and the leukocytes can be obtained from patients with O— blood.
- Patients with AB+ blood are universal donors for plasma and patients with O- blood are universal donors for leukocytes.
- the leukocytes and/or plasma may be of any blood type.
- the plasma used can be fresh, stored (e.g., at 1 -6°C. for less than 24 hours), dried, or otherwise pre-treated (e.g., pathogen-reduced plasma and solvent/detergent (SD) treated plasma).
- SD solvent/detergent
- the cells may be obtained from autologous samples, by apheresis, or from umbilical cord blood. Regardless of the source, all necessary processing of the sample(s) can be carried out without the need for highly specialized equipment.
- the method for making an ALC includes the steps of subjecting leukocytes, which may be obtained from a sample of whole human blood, to a first incubation for a period of time and at a temperature which allows the leukocytes to become activated, which in some embodiments, is about 8 to about 20 hours, and at room temperature. After incubation, the leukocytes are contacted with a physiologically acceptable aqueous solution such as sterile, distilled water, to initiate hypo-osmotic shock, followed by contacting the shocked leukocytes with a physiologically acceptable salt solution to restore isotonicity.
- This ALC may be used therapeutically.
- a sample of plasma which may be obtained from the same or different whole blood sample (i.e., from the same or a different human), is contacted with a coagulating agent at about 37° C concurrent with the leukocyte incubation, which in some embodiments, is about 8 to about 20 hours, followed by separating serum from the coagulated plasma sample.
- the leukocytes are resuspended in serum collected from the coagulated plasma sample, thus forming the ALC.
- the leukocytes may be further subjected to a second incubation for about 60 to about 120 minutes at about 37° C.
- the ALC will include leukocytes, e.g., granulocytes, monocytes and lymphocytes.
- Granulocytes include neutrophils, eosinophils and basophils.
- the leukocyte population of the ALC generally contains about 40% to about 90% granulocytes, about 5% to about 20% monocytes and about 5% to about 30% lymphocytes. Specific amounts of the cells may differ based on the analysis techniques employed.
- the leukocyte composition When analysis is performed using Fluorescence-Activated Cell Sorting (FACS) (e.g., using a side-scatter versus a forward-scatter dot plot analysis), the leukocyte composition generally contains about 55% to about 80% granulocytes; about 5% to about 15% monocytes and about 5% to about 30% lymphocytes, and in some embodiments, comprises about 58-76% granulocytes; about 5-1 1 % monocytes and about 9-23% lymphocytes. When analysis is performed using a Cell Dyn Analyzer, the leukocyte composition generally contains about 50% to about 90% granulocytes; about 5% to about 15% monocytes; and about 10% to about 25% lymphocytes.
- FACS Fluorescence-Activated Cell Sorting
- the subpopulation of lymphocytes in the ALC may confirm the following cells in the general ranges as follows: about 7% to about 25% B cells (CD19+); about 20% to about 30% NK cells (CD3-/CD56+), about 40% to about 60% T cells (CD3+); about 0.1 % to about 30% of NKT cells CD3+/CD56+, about 8% to about 20% of T helper cells (CD4+/CD3+), and about 20% to about 30% of CD8+/CD3+ cells.
- the lymphocyte subpopulation is enriched with at least 9% CD56+ cells (CD3-/CD56+; CD3+/CD56+; CD3+/CD56+/CD8+), the amount of the T helper lymphocytes (CD4+/CD3+) is decreased to less than 20%, and/or the ratio of T-helper to T-suppressor cells (CD4+/CD3+: CD8+/CD3+) is less than 0.8.
- the ALC may also include stem and progenitor cell populations.
- the ALC may further contain mesenchymal stem cells and endothelial progenitor cells, each in amounts ranging from about 0.1 % to about 5.0% of the total cell population in the ALC.
- leukocyte activation is defined as a process involving at least one stage, by which the cells (leukocytes) undergo a transition from a quiescent to a functionally active state which is accompanied by synthesis of biologically active substances or translocation of pre-synthesized substances, e.g., cytokines including IL-8, from the cytoplasm to the cellular membrane or their release into extracellular medium (which in this case is serum).
- cytokines including IL-8
- Activation of leukocytes in vivo may involve migration of the cells closer to and along the blood vessel wall, which is mediated by P-selectin (and increased CD42b expression), increased adhesion of leukocytes to the endothelial wall, spreading and extravasation, which is mediated to a large degree by activated CD 1 l b that interacts with endothelial ligands ICAM-1 and ICAM-2; migration to the focus of inflammation via interaction with extracellular matrix proteins, e.g., laminin) and functional responses to inflammatory stimuli such as respiratory burst, degranulation, phagocytosis and release of cytokines.
- inflammatory stimuli such as respiratory burst, degranulation, phagocytosis and release of cytokines.
- Activation of the leukocytes may also be indicated by increased expression of activated form of CD 1 l b receptor on leukocyte populations including granulocytes, monocytes and lymphocytes.
- CD62L is an adhesion receptor from a selectin family. It is constitutively expressed on all classes of leukocytes including granulocytes, monocytes and lymphocytes.
- leukocytes Upon activation, leukocytes rapidly shed off CD62L from their surface.
- CD62L is a plasma membrane protein which is shed during activation and thus decreases with cell activation.
- activated leukocytes may exhibit decreased levels of CD62L.
- activated leukocytes may also exhibit increased levels of CD68, a lymphocyte-specific marker, increased levels of cell surface receptor HLA-DR, and/or increased production of IL-8.
- indicia of leukocyte activation may include increased production of one or more of proteins or polypeptides, lipids, sugars, oxygen radicals and other biochemical moieties that function as adhesion molecules, cytokines in addition to IL-8, growth factors, enzymes, transcription factors and cell signaling receptors and mediators. Altered expression levels of any of these molecules is assessed from the standpoint of the leukocytes contained in a "fresh buffy coat" (as described herein), without being subjected to an incubation.
- ALCs activated leukocyte compositions
- Retaining leukocyte activity is defined herein as the leukocytes remaining activated once they are activated.
- leukocyte activity is indicated by the expression level of cell surface markers of activation.
- the indicators of retained leukocyte activity, based the expression level cell surface markers of activation include but are not limited to greater expression levels of GD I lb, greater expression levels of CD68, greater expression levels of HLA-DR, and lower expression levels of CD62L compared to those of the leukocytes contained in a "fresh buffy coat" (as described herein), without being subjected to an incubation.
- leukocyte activity is also indicated by secretion of certain cytokine(s), growth factor(s), or soluble mediator(s).
- an ALC retaining leukocyte activity has a concentration of at least one cytokine(s), growth factor(s), or soluble mediator chosen, for example, from IL-8, PDGF, Ang- 1 , VEGF, IL-6, TNF-alpha, or IL- ⁇ , that is at least about 1.25, 1 .5, 2, 3, 4, 5, 6, 7, 8. 9, 10 or more times the concentration of that same cytokine, growth factor, or soluble mediator in the same medium used to prepare the incubation composition that resulted in that ALC, but prior to contact of the medium with an activated leukocyte composition.
- Retaining leukocyte stability is defined herein as the ALC meeting the stability specifications as described herein.
- Stability specifications of the ALC include at least high viability of leukocytes, high concentration of leukocytes, high percentage of lymphocytes, and high percentage of activated granulocytes.
- the ALCs stored according to the present disclosure, may contain at least 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or greater, viable leukocytes based on this total number of leukocyte cells in the ALC (including all sub-ranges thereof).
- the ALCs stored according to the present disclosure, may have a leukocyte concentration (cells/ml) of at least l xl O 6 , 1.5xl 0 6 , 2x l 0 6 , 2.5x 10 6 , 3x l 0 6 , 3.5xl 0 6 , 4x l 0 6 , or greater (including all sub-ranges thereof).
- the ALCs stored according to the present disclosure, may contain at least
- lymphocytes based on this total number of leukocyte cells in the ALC (including all sub-ranges thereof).
- the ALCs stored according to the present disclosure, may contain at least
- CD 1 lb(+) granulocytes relative to the total granulocyte population in the ALC (including al l sub-ranges thereof).
- the activated leukocyte composition (ALC) is placed and stored under cold temperature immediately after production.
- the activated leukocyte composition is placed and stored under cold temperature after being stored at room temperature or other suitable temperature.
- cold temperature refers to a temperature that is below room temperature, for example, above 0° C and below about 10° C. In some embodiments, the range is from about 2° C to about 8° C, and in other embodiments from about 4° C to about 6° C. In one embodiment, the temperature is 5° C.
- room temperature refers to a temperature in the range of about 18° C to about 28° C, and more typically, about 20° C to about 24° C.
- the activated leukocyte composition is placed and stored under cold temperature, wherein the cold temperature is provided and maintained by a refrigerator or any suitable temperature controlling device.
- the ALC stored according to the present disclosure, has a shelf life (i.e., can be stored prior to use) extending up to 8 days following end of production, for example about 1 , 2, 3, 4, 5, 6, 7 or more days following its production.
- the ALC stored according to the present disclosure, has a shelf life extending up to 10 days following collection of the blood sample or blood samples used to prepare the ALC, that is, about 1 , 2, 3, 4, 5, 6, 7, 8, 9 or more days following collection of the blood sample or blood samples used to prepare the ALC.
- the ALC, stored according to the present disclosure can be used and applied according to the disclosure in U.S. Patent No. 8,574,902.
- the ALC is useful in promoting healing in a multitude of wound types. Although in practice it may be used in combination with other treatment modalities, it does not require them to achieve effective wound healing.
- the ease of application e.g., with a standard syringe or similar application device, makes the ALC compositions safe and easy to use.
- Wounds amenable to treatment with the ALC are typically in the form of burns, punctures, and cuts or tears of the living tissues. Wounds of the skin can penetrate the epidermis, dermis or in the case of full-thickness wounds, the subcutaneous tissue.
- representative types of wounds amenable to treatment with the compositions and methods of the present disclosure include burns (e.g., caused by exposure to fire or an agent that is highly caustic to skin such as radiation), ulcers (e.g., decubital or pressure ulcers; venous ulcers and diabetic ulcers), deep sternal wounds, e.g., following open heart surgery; and post-operative wounds following abdominal, orthopedic and any other types of surgery.
- wounds are those which result from trauma such as incurred during combat or other violent activity, including wounds caused by gun shots, knives, or any other object able to cause a cut or tear in the skin.
- Wounds of the oral cavity e.g., teeth
- wounds that arise as a side-effect of medication or as a symptom of various pathologies e.g., sores associated with Kaposi's Sarcoma
- internal wounds e.g., ruptures of muscle tissue such as anal fissures
- wounds or lesions to the gastrointestinal tract such as ulcers in the stomach or intestines
- the ALC may also provide a benefit of inhibiting onset of infection following such therapy, particularly in the context of surgery.
- the ALC may also be used to treat any wounds exacerbated by vascular insufficiency.
- Vascular insufficiency refers to inadequate blood circulation resulting in insufficient perfusion to the afflicted areas.
- Such insufficiency can be caused by trauma (e.g., damage to the vasculature adjacent to a skeletal fracture), or various pathologies (e.g., diabetes and atherosclerosis). In either instance, whether trauma or disease induced, vascular insufficiency decreases the likelihood of effective wound healing.
- the ALC may be useful in improving wound healing outcomes in these patients and should be administered according to the methods described herein. Additionally, treatment algorithms should not be limited by the severity or type of wound, or the extent of vascular insufficiency. ALC may be more efficacious in patients presenting with the most severe wounds and vascular insufficiency.
- application of the activated leukocyte composition is accomplished by means of one or more injections of the ALC at a single or multiple sites, using a suitable syringe (e.g., a 2 ml syringe fitted with an 1 8 G or 25 G needle) directly into the wound or the tissue surrounding the wound.
- a suitable syringe e.g., a 2 ml syringe fitted with an 1 8 G or 25 G needle
- injection occurs about every one centimeter to about every three centimeters for the entire length of the wound.
- At each injection site about 0.1 to about 0.3 ml of ALC is injected.
- ALC compositions of the present disclosure contain leukocytes in a concentration that generally ranges from about 2 10 6 cells/ml to about 4 l0 6 cells/ml.
- Luer-Lock syringe For injection into the wound, one may use a Luer-Lock syringe or any other commercially available syringe that has a locking mechanism between the syringe and the needle.
- the biological space of a wound, particularly a pressure wound, is often limited.
- a locking syringe eliminates this risk.
- the ALC can be applied directly into the cavity of the wound.
- Application in this method can be done using direct application with a syringe or tubing.
- the ALC may be applied to or around the wound site with the aid of a dressing.
- Dry dressings include gauze and bandages, non-adhesive meshes, membranes and foils, foams, and tissue adhesives.
- Moisture-keeping barrier dressings include pastes, creams and ointments, nonpermeable or semipermeable membranes or foils, hydrocolloids, hydrogels, and combination products.
- Bioactive dressings include antimicrobial dressings, interactive dressings, single-component biologic dressings, and combination products (e.g., ointments, gels, fibrin sealant, growth and angiogenic factors (e.g., PDGF, BEGF, collagen)).
- the wound is packed with sterile gauze soaked in the ALC.
- the dressing such as sterile gauze pads, may be saturated with compositions such as Lactated Ringer (Hartman) Solution, alginate containing dressing, polyurethane dressing or carboxymethylcellulose dressing, which is applied to cover the wound, followed by application of dry dressing. If the subject wound is highly infected, then silver dressings such as Silverlon can be applied.
- the choice of post- injection dressing is based on the determination of the clinician. Commercial availability, history of past clinical success, and patient tolerance are all factors to be considered in the selection of a wound dressing.
- the dressing may be removed periodically, e.g., typically after about 24 hours, in order to irrigate the wound e.g., with sterile water and soap.
- the ALC composition is combined with a physiologically inert and/or resorbable matrix or scaffold prior to administration.
- the matrix or scaffold may be formed from any material suitable for implantation into a person.
- the matrix or scaffold may comprise any biocompatible material including collagen, hyaluronic acid, or gelatin, or combinations thereof.
- the collagen may be obtained from any source, including collagen prepared from human tissue or the tissue of other collagen-producing mammals.
- the combination of the ALC composition and matrix/scaffold material may form a gel or putty that is administered to a person by means of a press fit, or by injection. This allows for a sustained delivery of the ALC into the site which benefits the patient in that the cells have a longer period in situ.
- the mixture of the ALC composition and matrix/scaffold material is prepared commercially and provided to a health-care provider pre-mixed.
- the health care provider mixes the ALC composition and the matric/scaffold prior to administration to a person.
- the ALC compositions may be applied to the wound once or more than once, e.g., after 4 weeks, once a clinician determines whether another application is necessary. Factors that may be taken into account include increased wound dimensions (width, length and depth), suppuration, pyrexia or any other sign or symptom indicating a recalcitrant infection such that re-treatment is warranted. In addition to re- treatment, referral for surgical debridement may be indicated at any point the clinician deems appropriate.
- the ALC may be used in conjunction with any other conventional wound treatment, such as negative pressure, warming (therapeutic heat), electrical stimulation, magnetism, laser phototherapy, cycloidal vibration therapy and ultrasound. It also can be used with biological therapy such as larva therapy, skin substitutes, cultured keratinocytes (Epicel, Genzyme biosurgery), human dermal replacement (Dermagraft, Organogenesis Inc. Inc.), cadaver derived processed dermis ( Alloderm, Life Cell Corporation), Bilayered Skin Equivalent (Apligraf, Organogenesis Inc.), TransCyte (Smith and Nephew Inc.), Growth Factors (PDGF is currently the only growth factor licensed for topical use), and fibrin sealant.
- biological therapy such as larva therapy, skin substitutes, cultured keratinocytes (Epicel, Genzyme biosurgery), human dermal replacement (Dermagraft, Organogenesis Inc. Inc.), cadaver derived processed dermis ( Alloderm, Life Cell Corporation), Bilayered Skin Equivalent (A
- the ALC is used in conjunction with negative pressure wound therapy (NPWT) (one example being the V.A.C., which is a commercially available wound therapy manufactured by KC1). Negative pressure therapy promotes wound healing by applying negative pressure to a wound.
- NGWT negative pressure wound therapy
- ALC may be applied to a wound prior to negative pressure therapy.
- the ALC is used in conjunction with hyperbaric oxygen therapy (Thackham, 2008) or ozone therapy.
- the ALC can be applied to a wound just prior to a patient receiving hyperbaric therapy.
- the ALC may also be used in conjunction with low-energy shock wave therapy (e.g., impulses of about 0.1 mJ/mm 2 ; 5 Hz) per centimeter of wound length). See, e.g., Dumfarth, et al., Ann. Thorac. Surg. 86: 1909-13 (2008).
- the wounds may be evaluated for length, width and height measurements.
- a wound is considered healed when all measurements of these parameters are negligible.
- the ALC may also provide an analgesic effect.
- the ALC is particularly useful in wounds including diabetic foot ulcers and decubital ulcers.
- Decubital ulcers are pressure ulcers caused by impeded blood flow, usually due to prolonged pressure on a particular area. (Berlowitz, 2007) Decubital ulcers cause morbidity and mortality in elderly people. At least 48% of stage 1 V pressure ulcers remain unhealed after one year of treatment. (Girouard, 2008). Patients suffering from decubiti also commonly have co-morbid pathologies such as diabetes and hypertension. These pathologies further complicate the successful treatment of decubiti.
- the composition is aspirated into a sterile syringe of any size, using an 18-gauge (18G) needle. Aspiration is performed slowly to minimize damage to the cells. While the size of the syringe and needle are by no means limiting, a large gauge needle is useful for aspiration. This facilitates the transfer and reduces cell damage.
- 18G 18-gauge
- Application of the ALC to the ulcer comprises injecting the composition into the wound.
- the entire sample in the syringe can be deployed and the clinician can choose to administer additional ALC if it is determined to be necessary based on clinical parameters.
- the 18G needle used for aspiration is exchanged with a needle ranging in size from 22-35 G.
- the ALC may be injected into the wound in various locations. In one embodiment, injection occurs about every one centimeter to about every three centimeters for the entire length of the wound. At each injection site, 0.1 -0.3 ml of ALC is injected. In another embodiment, the entire syringe can be injected at one time into a single site within the wound.
- Leukocytes and plasma from a typical blood component separation were obtained from a blood bank.
- the leukocytes and plasma were transferred into a custom bag set, such as described in U.S. Patent 8,574,902.
- Buffered CaCl 2 solution was added to bag containing the donor plasma.
- the plasma bag was then placed in an incubator at 37 ⁇ 1 °C for 12 ⁇ 2 hours. During this incubation the plasma converted into serum.
- the leukocytes are incubated at 20-24°C for the same 12 ⁇ 2 hour period.
- the bag set was removed from the incubator and pharmaceutical grade sterile water (200 mL) was added to the leukocytes and incubated for 45 ⁇ 5 seconds followed by the addition of buffered 9% NaCl solution to the leukocyte suspension to re-establish the isotonicity of the leukocyte preparation.
- the bags were than centrifuged at 1820 X g, at 20-24°C for 5 minutes to pellet the leukocytes and to enable subsequent removal of the buffered sodium chloride supernatant from the leukocyte bag. After centrifugation, the supernatant from the leukocyte-containing bag was transferred into a waste bag.
- the leukocyte cell pellet was suspended in the autologous serum and the cell suspension was then incubated for 90 ⁇ 5 minutes at 37 ⁇ 1 °C. After this incubation, the bag set was removed from the incubator and the serum was removed from leukocytes and fresh serum was added to the leukocytes.
- a sample of the leukocyte suspension was removed to permit a cell count.
- the leukocyte concentration was adjusted by adding a portion of serum so that the final cell concentration was between 3.6 x 10 6 to 4 x 10 6 cells/mL.
- All three FP batches were stored immediately after production at 2-8° C. Testing of the stored FP batches was performed within 20 minutes after they were pulled out the cold storage. During the 20- minute period, the storage bags containing the FP were gently massaged by hand, gently resuspended using a sterile syringe with 21 G needle, and sampled. The three FP batches were sampled immediately after production and before storage (time "0") and at 1 , 3, 4, 5, 6 and 7 days post-production. These batches were tested for leukocyte viability (Example 2), leukocyte concentration (Example 3), lymphocyte percentage (Example 4), and granulocyte activation (Example 5).
- the leukocyte (WBC) viability of the three FP batches before and after storage at 2-8° C was tested. Control cells were incubated at room temperature (20°-24° C) for 27 hours. These conditions were chosen based on prior knowledge that ALCs incubated at room temperature for more than 27 hours are no longer suitable for commercial use. The number of viable WBCs contained within the total WBCs population, expressed as a percentage, was measured. The results are presented in FIG. 1 A.
- FIG I B shows an analysis of white blood cell viability before and after storage.
- the three FP batches were tested for leukocyte (WBC) concentration before and after storage at
- lymphocyte percentage of the three FP batches before and after storage at 2-8° C was tested.
- Granulocyte activation which serves as a measurement of potency, of the three FP batches was tested using CD 1 1 b as an activation marker.
- Leukocytes were stained with an antibody against an activated form of CD1 lb (clone CBRM l/15) conjugated to phycoerythrin (PE) before and after storage at 2-8° C.
- the shortest stability is determined by Batch 1 .
- the lower 95% confidence limit of Batch 1 intersects with the lower cutoff criterion (50 MFl) after 12.0 days storage at 2-8° C.
- the lower 95% confidence limit of Batch 2 intercepts with the lower cutoff criterion after 18.5 days at 2-8° C.
- the lower 95% confidence limit of Batch 3 never intercepts with the lower cutoff criterion.
- FP batches from three different donors were prepared and stored in storage bags as described in Example 1.
- the activation status of the cells of the starting material (Fresh Buffy Coat, or FBC) and those of the FP were tested before storage (FP), 27 hours post-production at room temperature (RT; 20°-24° C), and 27 hours, 1 , 3, 4, 5, 6, and 7 days post production at 2-8° C (RF).
- the activation status was measured by analyzing cell surface markers of activation (CD1 lb, CD62, CD68 and HLA-DR), and by measuring pro-inflammatory cytokine secretion. For example, IL-8 secretion (pg/ml) into Roswell Park Memorial Institute medium (RPMI) containing serum, into serum, and internal IL-8 (i.e., not secreted), was measured.
- Cell surface markers of activation (CD1 l b, CD62L, CD68, and HLA-DR) were stained with corresponding antibodies and their expression levels were analyzed. The viability and sterility of the cells was also tested to show that potency observed reflects the activity of live cells, and that cell activation was due to the hypoosmotic-shock step rather than contamination. The results are presented in Tables 1 -3.
- the fluorescent intensity of all three batches (i.e., Batches 4, 5, and 6) stained with anti-CD l l b antibody were at least 30% higher at all time points as compared to the intensity of the Fresh Buffy Coat (FBC) stained with anti-CDl l b.
- the IL-8 concentrations for these three batches were at least 30% higher at all time points as compared to the IL-8 concentration in the Fresh Buffy Coat (FBC).
- the fluorescent intensity of all three batches stained with ant i-CD62L antibody were at least 30% lower at all time points as compared to the intensity of the Fresh Buffy Coat (FBC) stained with anti-CD62L.
- the fluorescent intensity of all three batches stained with anti-CD68 antibody were at least 30% higher at all time points as compared to the intensity of the Fresh Buf
- the fluorescent intensity of all three batches stained with anti-HLA-DR antibody were at least 30% higher at all time points as compared to the intensity of the Fresh Buffy Coat (FBC) stained with anti-HLA-DR antibody.
- lymphocyte percentage As shown in FIG. 1 1 , a significant increase was observed in lymphocyte percentage over the storage period of time. The percentage exceeded 43% after 2 days storage at RT.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed are storage solutions for activated leukocyte compositions. More particularly, disclosed are storage solutions that allow activated leukocyte compositions to be stored for an extended period of time at reduced temperatures, while retaining leukocyte stability and activity over time.
Description
METHODS FOR EXTENDED STORAGE OF ACTIVATED LEUKOCYTE COMPOSITIONS
This application is entitled to and claims the benefit of priority from United States Provisional Application No. 62/078, 165 filed November 1 1 , 2014, the contents of which are expressly incorporated herein by reference.
BACKGROUND
The wound healing process involves participation of white blood cells, also known as leukocytes. Leukocytes include lymphocytes, granulocytes and monocytes. Three common types of lymphocytes are T-cells, B-cells and natural killer cells. T-cells and B-cells play important roles in the recognition of antigens in the body (Parkin, 2001 ). Natural killer (NK) cells identify infected cells by alterations in the levels of the major histocompatability complex (MHC), and destroy the infected cells (Moretta, 2008). The participation of lymphocytes in the healing process is largely associated with their production of cytokines and growth factors (Keen, 2008). A new class of gamma-delta- T cells has been described in the skin (Jameson, 2002; Havran, 2005). Among the different types of granulocytes are neutrophils, basophils, and eosinophils. Monocytes differentiate into macrophages, which are responsible for destruction of tissue debris or invading foreign substances. Macrophages also produce molecules that control inflammation and repair (Riches, 1996). All of these cells types contribute to the process of wound healing in mammals.
The process of wound healing occurs in three overlapping phases. (Li, 2007; Broughton, 2006; Tsirogianni, 2006; Singer, 1999; Martin, 1997). The first phase is the inflammatory phase. It is characterized by recruitment of neutrophils, followed by monocytes to the wound site, where they kill and phagocytize bacteria (Agaiby, 1999).
The second wound healing phase which is known as the proliferative phase, involves formation of new granulation tissue. Fibroblasts proliferate and migrate into the wound space and synthesize collagen and other components of extracellular matrix (Greiling, 1997). At the same time, angiogenesis occurs, providing nutrients and oxygen to the metabolically active new granulation tissue (Tonnesen,
2000). Keratinocytes from the intact epidermis start to migrate over the provisional matrix and begin to proliferate, leading the way for new epithelial tissue (Kim, 1992).
Remodeling is the third and final phase in wound healing. It is characterized by fibroblast differentiation into myofibroblasts, which contract and bring the wound edges closer together (Tomasek, 2002). Remodeling of the collagen fibers by degradation and re-synthesis allows the wound to gain strength by re-orientation of the collagen fibers (a process tightly controlled by growth factors) (Werner, 2003).
Activated leukocyte compositions (ALC) for repairing or promoting the prevention and healing of wounds, and methods of making and using ALCs, are described in U.S. Patent No. 8,574,902 and related U.S. Patent Application Publication Nos. 2013/0071465 and 2014/0004091 , each of which is incorporated by reference in its entirety. As these references describe, after production the ALC is typically stored at room temperature, for example, at approximately 20-24° C. This temperature is
maintained throughout the ALC production procedure (except for incubation steps). The ALC is also maintained at this temperature during any periods of shipping, up until and including the point in time that the ALC is administered to a subject with a wound in need of treatment. Maintained at room temperature, the ALC has a commercially useful shelf life of up to 50 hours measured from the time of blood donation, or 27 hours after completing production of the ALC. This relatively short shelf life places a logistical constraint on the manufacturing, shipping and distribution, and therapeutic use of the ALC. Such problems are particularly acute in the case of large-scale ALC production required to address market demands, which implies a large number of participating donors and relatively long-term storage before the product is administered to patients. A suitable storage solution is also critical since the ultimate therapeutic efficacy for the ALC depends on the activity profile of the leukocytes, which may change over time as the various subsets of cells in the ALC respond to storage conditions in different ways. Therefore, it is desirable to provide a storage solution that allows the ALC to be stored for extended periods of time before its therapeutic use and, at the same time, provides a good retention of leukocyte stability and activity over time.
BRIEF SUMMARY OF THE DISCLOSURE
The present embodiments described are on the discovery that storing an activated leukocyte composition (ALC) under at temperatures below room temperature provides for good retention of leukocyte stability and activity of the ALC for extended periods of time.
There is disclosed a method for the storing an activated leukocyte composition comprising providing the activated leukocyte composition, and maintaining the activated leukocyte composition at a temperature ranging from above 0° C to below about 10° C. In some of the disclosed methods, the temperature ranges from about 2° C to about 8° C. In other disclosed methods the temperature ranges from about 4° C to about 6° C. In one method, the temperature is about 5° C.
In some of the disclosed methods, the activated leukocyte composition is maintained at a temperature ranging from 2° C to about 8° C for about 1 , 2, 3, 4, 5, 6, or 7 days. In other disclosed methods, the activated leukocyte composition is maintained at a temperature ranging from about 4° C to about 6° C for about 1 , 2, 3, 4, 5, 6, or 7 days. On other disclosed methods, the activated leukocyte composition is maintained at a temperature of about 5° C for about 1 , 2, 3, 4, 5, 6, or 7 days.
Also disclosed herein is an activated leukocyte composition stored at a temperature ranging from above 0° C to below about 10° C. In some embodiments, the composition comprises serum. In other embodiments, at least 85% of cells in the activated leukocyte composition remain viable after seven days of storage. In other embodiments, at least 90% of cells in the activated leukocyte composition remain viable after seven days of storage.
Also disclosed is a method for prolonging the activity of leukocytes in an activated leukocyte composition comprising providing the activated leukocyte composition, and
maintaining the activated leukocyte composition at a temperature ranging from above 0° C to below about 10° C. In some embodiments, the temperature ranges from about 2° C to about 8° C. In other
embodiments, the temperature ranges from about 4° C to about 6° C. In another embodiment, wherein the temperature is about5° C.
in some of the disclosed methods, the activated leukocyte composition is maintained at a temperature ranging from 2° C to about 8° C for about 1 , 2, 3, 4, 5, 6, or 7 days. In other disclosed embodiments, the activated leukocyte composition is maintained at a temperature ranging from 4° C to about 6° C for about 1 , 2, 3. 4, 5, 6, or 7 days. In additional disclosed methods, the activated leukocyte composition is maintained at a temperature of about 5° C for about 1 , 2, 3, 4, 5, 6, or 7 days.
Also disclosed are activated leukocyte compositions comprising leukocytes having prolonged activity made according to the methods disclosed herein.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates the leukocyte (or white blood cell, hereinafter WBC) viability of three final product (FP) batches before and after storage at 2-8° C. WBCs viability was measured at time "0" (i.e., before storage) and after storage and plotted against post-production days. Linear regression analysis for WBC viability was performed. The dotted lines represent the 95% confidence limits of the linear regression analysis for the plotted data line for each FP batch.
FIG. 2 illustrates the leukocyte (WBC) concentration of three FP batches before and after storage at 2-8° C. WBCs concentration was measured with a Cell Dyn Analyzer at time "0" (i.e., before storage) and after storage and plotted against post-production days. Linear regression analysis for WBCs concentration was performed. The dotted lines represent the 95% confidence limits of the linear regression analysis for the plotted data line for each FP batch.
FIG. 3 illustrates the lymphocyte percentage of the three FP batches before and after storage at 2- 8° C. Lymphocyte percentage was measured with a Cell Dyn Analyzer at time "0" (i.e., before storage) and after storage and plotted against post-production days. Linear regression analysis for lymphocyte percentage was performed. The dotted lines represent the 95% confidence limits of the linear regression analysis for the plotted data line for each FP batch.
FIG. 4 illustrates the granulocyte activation (potency) of the three FP batches before and after storage at 2-8° C. Leukocytes were stained with the antibody against activated form of CD 1 l b (clone CBRMl/15) conjugated to phycoerythrin (PE) at time "0" (i.e., before storage) and after storage. Mean Florescence Intensity (MFI) of the CD 1 lb staining was plotted against post-production days. Linear regression analysis for MFI was performed. The dotted lines represent the 95% confidence limits of the linear regression analysis for the plotted data line for each FP batch.
FIG 5 provides an analysis of CD1 l b expression of ALCs before and after storage.
FIG. 6 provides an analysis of IL-8 content of ALCs before and after storage.
FIG. 7 provides an analysis of CD62L expression of ALCs before and after storage.
FIG. 8 provides an analysis of CD68 expression of ALCs before and after storage.
FIG. 9 provides an analysis of HLA-DR expression of ALCs before and after storage.
FIG. 10 shows the effect on WBC concentration when activated leukocytes are stored at room temperature.
FIG. 1 1 shows effect on leukocyte percentage when activated leikocytes are stored at room temperature.
DETAILED DESCRIPTION
Blood is defined herein as whole blood or any of its constituent parts (e.g., plasma, leukocytes, platelets or red blood cells). The amounts of platelets and red blood cells that may be present in the ALC may be lower than that in whole blood.
The term "about" as used herein in connection with any and all values (including lower and upper ends of numerical ranges) means ±10%.
The starting materials for producing the ALCs may be obtained from several sources. Whole blood or one or more components thereof (e.g., leukocytes and plasma) may be obtained from autologous or allogeneic sources. In one embodiment, the blood sample is collected from the patient who will ultimately be treated with the ALC, which is referred to herein as an autologous blood sample or source. In embodiments wherein the source(s) i.e., the blood or its components, is obtained from an individual other than the intended ALC recipient, which is referred to as an allogeneic blood sample or source, these starting materials may be conveniently obtained from a blood bank. The samples may be screened by the blood bank for blood type (ABO, Rh), irregular antibodies to red cell antigens, and transfusion- transmittable diseases. More specifically, screening can be conducted with antibodies using an Abbott PRISM instrument against: Hepatitis B, C, HIV 1/2, HTLV and Syphilis (-HCV; HbsAg; anti-HIV 1/2 0+; and anti-HTLV I/II). The samples can also be screened for HIV, HCV and HBV by molecular methods (NAT-Nucleic Acid Testing). Molecular screening can be accomplished using commercially available instrumentation, e.g., the TIGRIS system of Chiron.
In these embodiments involving allogeneic sources, the samples can be obtained from donors with the same blood type as the intended ALC recipient. Alternatively and as further described herein, plasma samples can be obtained from donors with AB+ blood and the leukocytes can be obtained from patients with O— blood. Patients with AB+ blood are universal donors for plasma and patients with O- blood are universal donors for leukocytes. In still other embodiments, the leukocytes and/or plasma may be of any blood type. The plasma used can be fresh, stored (e.g., at 1 -6°C. for less than 24 hours), dried, or otherwise pre-treated (e.g., pathogen-reduced plasma and solvent/detergent (SD) treated plasma). The plasma can be fresh or stored at 1 -6° C. for less than 24 hours, or Fresh Frozen Plasma, or Dried Plasma, or Pathogen-Reduced Plasma, or Solvent/Detergent (SD) Treated Plasma. In addition to allogeneic sources, the cells may be obtained from autologous samples, by apheresis, or from umbilical cord blood. Regardless of the source, all necessary processing of the sample(s) can be carried out without the need for highly specialized equipment.
One method of making the ALCs is described in U.S. Patent No. 8,574,902, which is incorporated by reference in its entirety.
In some embodiments, the method for making an ALC includes the steps of subjecting leukocytes, which may be obtained from a sample of whole human blood, to a first incubation for a period of time and at a temperature which allows the leukocytes to become activated, which in some
embodiments, is about 8 to about 20 hours, and at room temperature. After incubation, the leukocytes are contacted with a physiologically acceptable aqueous solution such as sterile, distilled water, to initiate hypo-osmotic shock, followed by contacting the shocked leukocytes with a physiologically acceptable salt solution to restore isotonicity. This ALC may be used therapeutically. However, in some embodiments, separate and substantially concurrent with the first incubation of the leukocytes, a sample of plasma, which may be obtained from the same or different whole blood sample (i.e., from the same or a different human), is contacted with a coagulating agent at about 37° C concurrent with the leukocyte incubation, which in some embodiments, is about 8 to about 20 hours, followed by separating serum from the coagulated plasma sample. The leukocytes are resuspended in serum collected from the coagulated plasma sample, thus forming the ALC. After the first incubation, the leukocytes may be further subjected to a second incubation for about 60 to about 120 minutes at about 37° C.
The ALC will include leukocytes, e.g., granulocytes, monocytes and lymphocytes. Granulocytes include neutrophils, eosinophils and basophils. In its broadest sense, the leukocyte population of the ALC generally contains about 40% to about 90% granulocytes, about 5% to about 20% monocytes and about 5% to about 30% lymphocytes. Specific amounts of the cells may differ based on the analysis techniques employed. When analysis is performed using Fluorescence-Activated Cell Sorting (FACS) (e.g., using a side-scatter versus a forward-scatter dot plot analysis), the leukocyte composition generally contains about 55% to about 80% granulocytes; about 5% to about 15% monocytes and about 5% to about 30% lymphocytes, and in some embodiments, comprises about 58-76% granulocytes; about 5-1 1 % monocytes and about 9-23% lymphocytes. When analysis is performed using a Cell Dyn Analyzer, the leukocyte composition generally contains about 50% to about 90% granulocytes; about 5% to about 15% monocytes; and about 10% to about 25% lymphocytes. The subpopulation of lymphocytes in the ALC may confirm the following cells in the general ranges as follows: about 7% to about 25% B cells (CD19+); about 20% to about 30% NK cells (CD3-/CD56+), about 40% to about 60% T cells (CD3+); about 0.1 % to about 30% of NKT cells CD3+/CD56+, about 8% to about 20% of T helper cells (CD4+/CD3+), and about 20% to about 30% of CD8+/CD3+ cells. In some embodiments, the lymphocyte subpopulation is enriched with at least 9% CD56+ cells (CD3-/CD56+; CD3+/CD56+; CD3+/CD56+/CD8+), the amount of the T helper lymphocytes (CD4+/CD3+) is decreased to less than 20%, and/or the ratio of T-helper to T-suppressor cells (CD4+/CD3+: CD8+/CD3+) is less than 0.8. The ALC may also include stem and progenitor cell populations. For example, the ALC may further contain mesenchymal stem cells and endothelial progenitor cells, each in amounts ranging from about 0.1 % to about 5.0% of the total cell population in the ALC.
For purposes of this disclosure, leukocyte activation is defined as a process involving at least one stage, by which the cells (leukocytes) undergo a transition from a quiescent to a functionally active state which is accompanied by synthesis of biologically active substances or translocation of pre-synthesized substances, e.g., cytokines including IL-8, from the cytoplasm to the cellular membrane or their release into extracellular medium (which in this case is serum). Activation of leukocytes in vivo may involve migration of the cells closer to and along the blood vessel wall, which is mediated by P-selectin (and
increased CD42b expression), increased adhesion of leukocytes to the endothelial wall, spreading and extravasation, which is mediated to a large degree by activated CD 1 l b that interacts with endothelial ligands ICAM-1 and ICAM-2; migration to the focus of inflammation via interaction with extracellular matrix proteins, e.g., laminin) and functional responses to inflammatory stimuli such as respiratory burst, degranulation, phagocytosis and release of cytokines. Activation of the leukocytes may also be indicated by increased expression of activated form of CD 1 l b receptor on leukocyte populations including granulocytes, monocytes and lymphocytes. CD62L is an adhesion receptor from a selectin family. It is constitutively expressed on all classes of leukocytes including granulocytes, monocytes and lymphocytes. Upon activation, leukocytes rapidly shed off CD62L from their surface. CD62L is a plasma membrane protein which is shed during activation and thus decreases with cell activation. In some embodiments, activated leukocytes may exhibit decreased levels of CD62L. In some embodiments, activated leukocytes may also exhibit increased levels of CD68, a lymphocyte-specific marker, increased levels of cell surface receptor HLA-DR, and/or increased production of IL-8. Yet other indicia of leukocyte activation may include increased production of one or more of proteins or polypeptides, lipids, sugars, oxygen radicals and other biochemical moieties that function as adhesion molecules, cytokines in addition to IL-8, growth factors, enzymes, transcription factors and cell signaling receptors and mediators. Altered expression levels of any of these molecules is assessed from the standpoint of the leukocytes contained in a "fresh buffy coat" (as described herein), without being subjected to an incubation.
It is a purpose of this disclosure to provide storage solutions that allow activated leukocyte compositions (ALCs) to be stored for an extended period of time while retaining leukocyte stability and activity over time.
Retaining leukocyte activity is defined herein as the leukocytes remaining activated once they are activated. In some embodiments, leukocyte activity is indicated by the expression level of cell surface markers of activation. In some embodiments, the indicators of retained leukocyte activity, based the expression level cell surface markers of activation, include but are not limited to greater expression levels of GD I lb, greater expression levels of CD68, greater expression levels of HLA-DR, and lower expression levels of CD62L compared to those of the leukocytes contained in a "fresh buffy coat" (as described herein), without being subjected to an incubation.
In some embodiments, leukocyte activity is also indicated by secretion of certain cytokine(s), growth factor(s), or soluble mediator(s). In other embodiments, an ALC retaining leukocyte activity has a concentration of at least one cytokine(s), growth factor(s), or soluble mediator chosen, for example, from IL-8, PDGF, Ang- 1 , VEGF, IL-6, TNF-alpha, or IL-Ιβ, that is at least about 1.25, 1 .5, 2, 3, 4, 5, 6, 7, 8. 9, 10 or more times the concentration of that same cytokine, growth factor, or soluble mediator in the same medium used to prepare the incubation composition that resulted in that ALC, but prior to contact of the medium with an activated leukocyte composition.
Retaining leukocyte stability is defined herein as the ALC meeting the stability specifications as described herein. Stability specifications of the ALC include at least high viability of leukocytes, high
concentration of leukocytes, high percentage of lymphocytes, and high percentage of activated granulocytes.
In some embodiments, the ALCs, stored according to the present disclosure, may contain at least 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or greater, viable leukocytes based on this total number of leukocyte cells in the ALC (including all sub-ranges thereof).
In some embodiments, the ALCs, stored according to the present disclosure, may have a leukocyte concentration (cells/ml) of at least l xl O6, 1.5xl 06, 2x l 06, 2.5x 106, 3x l 06, 3.5xl 06, 4x l 06, or greater (including all sub-ranges thereof).
In some embodiments, the ALCs, stored according to the present disclosure, may contain at least
14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, 40% or greater, lymphocytes based on this total number of leukocyte cells in the ALC (including all sub-ranges thereof).
In some embodiments, the ALCs, stored according to the present disclosure, may contain at least
50%, 51 %, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%, 65%, 66%, 67%, 68%. 69%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, or higher, CD 1 lb(+) granulocytes, relative to the total granulocyte population in the ALC (including al l sub-ranges thereof).
In some embodiments, the activated leukocyte composition (ALC) is placed and stored under cold temperature immediately after production.
In some embodiments, the activated leukocyte composition (ALC) is placed and stored under cold temperature after being stored at room temperature or other suitable temperature.
For purposes of this disclosure, "cold temperature" refers to a temperature that is below room temperature, for example, above 0° C and below about 10° C. In some embodiments, the range is from about 2° C to about 8° C, and in other embodiments from about 4° C to about 6° C. In one embodiment, the temperature is 5° C.
For purposes of the present disclosure, "room temperature" refers to a temperature in the range of about 18° C to about 28° C, and more typically, about 20° C to about 24° C.
In one embodiment, the activated leukocyte composition (ALC) is placed and stored under cold temperature, wherein the cold temperature is provided and maintained by a refrigerator or any suitable temperature controlling device.
In one embodiment, the ALC, stored according to the present disclosure, has a shelf life (i.e., can be stored prior to use) extending up to 8 days following end of production, for example about 1 , 2, 3, 4, 5, 6, 7 or more days following its production.
In one embodiment, the ALC, stored according to the present disclosure, has a shelf life extending up to 10 days following collection of the blood sample or blood samples used to prepare the ALC, that is, about 1 , 2, 3, 4, 5, 6, 7, 8, 9 or more days following collection of the blood sample or blood samples used to prepare the ALC.
The ALC, stored according to the present disclosure, can be used and applied according to the disclosure in U.S. Patent No. 8,574,902.
For example, the ALC is useful in promoting healing in a multitude of wound types. Although in practice it may be used in combination with other treatment modalities, it does not require them to achieve effective wound healing. The ease of application, e.g., with a standard syringe or similar application device, makes the ALC compositions safe and easy to use.
Wounds amenable to treatment with the ALC are typically in the form of burns, punctures, and cuts or tears of the living tissues. Wounds of the skin can penetrate the epidermis, dermis or in the case of full-thickness wounds, the subcutaneous tissue. Thus, representative types of wounds amenable to treatment with the compositions and methods of the present disclosure include burns (e.g., caused by exposure to fire or an agent that is highly caustic to skin such as radiation), ulcers (e.g., decubital or pressure ulcers; venous ulcers and diabetic ulcers), deep sternal wounds, e.g., following open heart surgery; and post-operative wounds following abdominal, orthopedic and any other types of surgery. Other wounds are those which result from trauma such as incurred during combat or other violent activity, including wounds caused by gun shots, knives, or any other object able to cause a cut or tear in the skin. Wounds of the oral cavity (e.g., teeth), as well as wounds that arise as a side-effect of medication or as a symptom of various pathologies (e.g., sores associated with Kaposi's Sarcoma), as well as internal wounds (e.g., ruptures of muscle tissue such as anal fissures), and wounds or lesions to the gastrointestinal tract, such as ulcers in the stomach or intestines) may also be amenable to treatment with the present disclosure. In addition to providing a wound-healing effect, the ALC may also provide a benefit of inhibiting onset of infection following such therapy, particularly in the context of surgery.
The ALC may also be used to treat any wounds exacerbated by vascular insufficiency. Vascular insufficiency, for purposes of this disclosure, refers to inadequate blood circulation resulting in insufficient perfusion to the afflicted areas. Such insufficiency can be caused by trauma (e.g., damage to the vasculature adjacent to a skeletal fracture), or various pathologies (e.g., diabetes and atherosclerosis). In either instance, whether trauma or disease induced, vascular insufficiency decreases the likelihood of effective wound healing. The ALC may be useful in improving wound healing outcomes in these patients and should be administered according to the methods described herein. Additionally, treatment algorithms should not be limited by the severity or type of wound, or the extent of vascular insufficiency. ALC may be more efficacious in patients presenting with the most severe wounds and vascular insufficiency.
In general, application of the activated leukocyte composition is accomplished by means of one or more injections of the ALC at a single or multiple sites, using a suitable syringe (e.g., a 2 ml syringe fitted with an 1 8 G or 25 G needle) directly into the wound or the tissue surrounding the wound. In some embodiments, injection occurs about every one centimeter to about every three centimeters for the entire length of the wound. At each injection site, about 0.1 to about 0.3 ml of ALC is injected. ALC compositions of the present disclosure contain leukocytes in a concentration that generally ranges from about 2 106 cells/ml to about 4 l06 cells/ml.
For injection into the wound, one may use a Luer-Lock syringe or any other commercially available syringe that has a locking mechanism between the syringe and the needle. The biological space of a wound, particularly a pressure wound, is often limited. When injecting into a wound, there is a risk of pressure causing the syringe to separate from the needle. Using a locking syringe eliminates this risk.
When injection into the wound tissue is not possible, the ALC can be applied directly into the cavity of the wound. Application in this method can be done using direct application with a syringe or tubing.
The ALC may be applied to or around the wound site with the aid of a dressing. Dry dressings include gauze and bandages, non-adhesive meshes, membranes and foils, foams, and tissue adhesives. Moisture-keeping barrier dressings include pastes, creams and ointments, nonpermeable or semipermeable membranes or foils, hydrocolloids, hydrogels, and combination products. Bioactive dressings include antimicrobial dressings, interactive dressings, single-component biologic dressings, and combination products (e.g., ointments, gels, fibrin sealant, growth and angiogenic factors (e.g., PDGF, BEGF, collagen)). In some embodiments, the wound is packed with sterile gauze soaked in the ALC. The dressing, such as sterile gauze pads, may be saturated with compositions such as Lactated Ringer (Hartman) Solution, alginate containing dressing, polyurethane dressing or carboxymethylcellulose dressing, which is applied to cover the wound, followed by application of dry dressing. If the subject wound is highly infected, then silver dressings such as Silverlon can be applied. The choice of post- injection dressing is based on the determination of the clinician. Commercial availability, history of past clinical success, and patient tolerance are all factors to be considered in the selection of a wound dressing. The dressing may be removed periodically, e.g., typically after about 24 hours, in order to irrigate the wound e.g., with sterile water and soap.
In another embodiment, the ALC composition is combined with a physiologically inert and/or resorbable matrix or scaffold prior to administration. The matrix or scaffold may be formed from any material suitable for implantation into a person. For example, the matrix or scaffold may comprise any biocompatible material including collagen, hyaluronic acid, or gelatin, or combinations thereof. The collagen may be obtained from any source, including collagen prepared from human tissue or the tissue of other collagen-producing mammals. The combination of the ALC composition and matrix/scaffold material may form a gel or putty that is administered to a person by means of a press fit, or by injection. This allows for a sustained delivery of the ALC into the site which benefits the patient in that the cells have a longer period in situ. In some embodiments, the mixture of the ALC composition and matrix/scaffold material is prepared commercially and provided to a health-care provider pre-mixed. In other embodiments, the health care provider mixes the ALC composition and the matric/scaffold prior to administration to a person.
The ALC compositions may be applied to the wound once or more than once, e.g., after 4 weeks, once a clinician determines whether another application is necessary. Factors that may be taken into account include increased wound dimensions (width, length and depth), suppuration, pyrexia or any other
sign or symptom indicating a recalcitrant infection such that re-treatment is warranted. In addition to re- treatment, referral for surgical debridement may be indicated at any point the clinician deems appropriate.
The ALC may be used in conjunction with any other conventional wound treatment, such as negative pressure, warming (therapeutic heat), electrical stimulation, magnetism, laser phototherapy, cycloidal vibration therapy and ultrasound. It also can be used with biological therapy such as larva therapy, skin substitutes, cultured keratinocytes (Epicel, Genzyme biosurgery), human dermal replacement (Dermagraft, Organogenesis Inc. Inc.), cadaver derived processed dermis ( Alloderm, Life Cell Corporation), Bilayered Skin Equivalent (Apligraf, Organogenesis Inc.), TransCyte (Smith and Nephew Inc.), Growth Factors (PDGF is currently the only growth factor licensed for topical use), and fibrin sealant. In some embodiments, the ALC is used in conjunction with negative pressure wound therapy (NPWT) (one example being the V.A.C., which is a commercially available wound therapy manufactured by KC1). Negative pressure therapy promotes wound healing by applying negative pressure to a wound. In these embodiments, ALC may be applied to a wound prior to negative pressure therapy. In yet other embodiments, the ALC is used in conjunction with hyperbaric oxygen therapy (Thackham, 2008) or ozone therapy. For example, the ALC can be applied to a wound just prior to a patient receiving hyperbaric therapy. The ALC may also be used in conjunction with low-energy shock wave therapy (e.g., impulses of about 0.1 mJ/mm2; 5 Hz) per centimeter of wound length). See, e.g., Dumfarth, et al., Ann. Thorac. Surg. 86: 1909-13 (2008).
After treatment, the wounds may be evaluated for length, width and height measurements.
Typically, a wound is considered healed when all measurements of these parameters are negligible. The ALC may also provide an analgesic effect.
The ALC is particularly useful in wounds including diabetic foot ulcers and decubital ulcers. Decubital ulcers are pressure ulcers caused by impeded blood flow, usually due to prolonged pressure on a particular area. (Berlowitz, 2007) Decubital ulcers cause morbidity and mortality in elderly people. At least 48% of stage 1 V pressure ulcers remain unhealed after one year of treatment. (Girouard, 2008). Patients suffering from decubiti also commonly have co-morbid pathologies such as diabetes and hypertension. These pathologies further complicate the successful treatment of decubiti.
In one embodiment for treating decubital ulcers, the composition is aspirated into a sterile syringe of any size, using an 18-gauge (18G) needle. Aspiration is performed slowly to minimize damage to the cells. While the size of the syringe and needle are by no means limiting, a large gauge needle is useful for aspiration. This facilitates the transfer and reduces cell damage.
Application of the ALC to the ulcer comprises injecting the composition into the wound. The entire sample in the syringe can be deployed and the clinician can choose to administer additional ALC if it is determined to be necessary based on clinical parameters.
The 18G needle used for aspiration is exchanged with a needle ranging in size from 22-35 G.
The ALC may be injected into the wound in various locations. In one embodiment, injection occurs about every one centimeter to about every three centimeters for the entire length of the wound. At each injection site, 0.1 -0.3 ml of ALC is injected.
In another embodiment, the entire syringe can be injected at one time into a single site within the wound.
Aspect(s) of the present disclosure will now be described in accordance with the following non- limiting examples.
Example 1 : Production of Final Product Batches
Three ALC final product (FP) batches (referred to herein as Batches 1 , 2, and 3) from three different donors were prepared and stored in storage bags as follows.
Leukocytes and plasma from a typical blood component separation were obtained from a blood bank. The leukocytes and plasma were transferred into a custom bag set, such as described in U.S. Patent 8,574,902.
Buffered CaCl2 solution was added to bag containing the donor plasma. The plasma bag was then placed in an incubator at 37 ± 1 °C for 12±2 hours. During this incubation the plasma converted into serum. In parallel, the leukocytes are incubated at 20-24°C for the same 12±2 hour period.
Following this incubation, the bag set was removed from the incubator and pharmaceutical grade sterile water (200 mL) was added to the leukocytes and incubated for 45±5 seconds followed by the addition of buffered 9% NaCl solution to the leukocyte suspension to re-establish the isotonicity of the leukocyte preparation. The bags were than centrifuged at 1820 X g, at 20-24°C for 5 minutes to pellet the leukocytes and to enable subsequent removal of the buffered sodium chloride supernatant from the leukocyte bag. After centrifugation, the supernatant from the leukocyte-containing bag was transferred into a waste bag.
Following removal of the supernatant, the leukocyte cell pellet was suspended in the autologous serum and the cell suspension was then incubated for 90±5 minutes at 37± 1 °C. After this incubation, the bag set was removed from the incubator and the serum was removed from leukocytes and fresh serum was added to the leukocytes.
A sample of the leukocyte suspension was removed to permit a cell count. The leukocyte concentration was adjusted by adding a portion of serum so that the final cell concentration was between 3.6 x 106 to 4 x 106 cells/mL.
All three FP batches were stored immediately after production at 2-8° C. Testing of the stored FP batches was performed within 20 minutes after they were pulled out the cold storage. During the 20- minute period, the storage bags containing the FP were gently massaged by hand, gently resuspended using a sterile syringe with 21 G needle, and sampled. The three FP batches were sampled immediately after production and before storage (time "0") and at 1 , 3, 4, 5, 6 and 7 days post-production. These batches were tested for leukocyte viability (Example 2), leukocyte concentration (Example 3), lymphocyte percentage (Example 4), and granulocyte activation (Example 5).
Example 2: Analysis of Leukocyte Viability
The leukocyte (WBC) viability of the three FP batches before and after storage at 2-8° C was tested. Control cells were incubated at room temperature (20°-24° C) for 27 hours. These conditions were chosen based on prior knowledge that ALCs incubated at room temperature for more than 27 hours
are no longer suitable for commercial use. The number of viable WBCs contained within the total WBCs population, expressed as a percentage, was measured. The results are presented in FIG. 1 A.
Five quantitative attributes were plotted using linear regression analysis with 95% confidence limit. Only NC-I-032 demonstrates significant linear degradation (r2=0.73) with the lower 95% confidence limit intersecting 85% viability after 10.2 days storage at 2-8° C. Batches 2 and 3 demonstrated a slight non-significant decrease (r2=0.12 and 0.06, respectively) with the lower 95% confidence limit intercepting with the lower acceptance criterion after 37.2 and 15.5 days at 2-8° C, respectively.
FIG I B shows an analysis of white blood cell viability before and after storage. Batch 1 demonstrated slight non-significant decrease (r2=0.1 1 ) with the lower 95% confidence limit intercepting with the lower acceptance criterion after 57.8 hours at RT. Batches 2 and 3 demonstrated slight nonsignificant increase (r2=0.87 and 0.06 respectively). Note that separate viability counts, and not the final reported results, were used for the statistical analysis.
Example 3: Analysis of Leukocyte Concentration
The three FP batches were tested for leukocyte (WBC) concentration before and after storage at
2-8°C with a Cell Dyn Analyzer. The results are presented in FIG. 2. Based on the statistical analysis, the shortest stability is determined by Batch 1. The lower 95% confidence limit of Batch 1 intersects with the lower cutoff value (2.0 10b cells/ml) after 7.7 days storage at 2-8° C. The lower 95%> confidence limits of Batches 2 and 3 intercept with the lower cutoff value after 1 1.2 and 10.8 days at 2-8° C, respectively. All three batches tested in this study demonstrated significant linear degradation (r2=0.88, 0.87, and 0.88, respectively).
Example 4: Analysis of Lymphocyte Percentage
The lymphocyte percentage of the three FP batches before and after storage at 2-8° C was tested. The number of lymphocytes contained within the total leukocytes population, expressed as a percentage, was measured with a Cell Dyn Analyzer. The results are presented in FIG. 3.
Only Batch 3 demonstrated significant linear regression (r2=0.70), which shows a decrease in the lymphocyte percentage over time with no interception with the upper cutoff criterion of 46%. Batches 1 and 2 demonstrated a slight non-significant (r2=0.12 and 0.10 respectively) increase with the upper 95% confidence limit intercepting with the upper cutoff criterion after 34.7 and 29.2 days at 2-8° C, respectively.
Example 5: Analysis of Granulocyte Activation
Granulocyte activation, which serves as a measurement of potency, of the three FP batches was tested using CD 1 1 b as an activation marker. Leukocytes were stained with an antibody against an activated form of CD1 lb (clone CBRM l/15) conjugated to phycoerythrin (PE) before and after storage at 2-8° C. Mean Florescence Intensity (MFI) of the anti-CDl l b staining was plotted against post production (storage) time. Linear regression analysis for MFI including 95% confidence interval for the individual predicted value was performed. The results are presented in FIG. 4.
All three batches tested in this study demonstrate non-significant linear degradation (r2=0.48, 0.01 and 0.01 , respectively). Based on the statistical analysis the shortest stability is determined by Batch 1 . The lower 95% confidence limit of Batch 1 intersects with the lower cutoff criterion (50 MFl) after 12.0 days storage at 2-8° C. The lower 95% confidence limit of Batch 2 intercepts with the lower cutoff criterion after 18.5 days at 2-8° C. The lower 95% confidence limit of Batch 3 never intercepts with the lower cutoff criterion.
Example 6: Comparative Analysis of ALCs Stored at Different Temperatures
Three FP batches from three different donors were prepared and stored in storage bags as described in Example 1. The activation status of the cells of the starting material (Fresh Buffy Coat, or FBC) and those of the FP were tested before storage (FP), 27 hours post-production at room temperature (RT; 20°-24° C), and 27 hours, 1 , 3, 4, 5, 6, and 7 days post production at 2-8° C (RF).
The activation status was measured by analyzing cell surface markers of activation (CD1 lb, CD62, CD68 and HLA-DR), and by measuring pro-inflammatory cytokine secretion. For example, IL-8 secretion (pg/ml) into Roswell Park Memorial Institute medium (RPMI) containing serum, into serum, and internal IL-8 (i.e., not secreted), was measured. Cell surface markers of activation (CD1 l b, CD62L, CD68, and HLA-DR) were stained with corresponding antibodies and their expression levels were analyzed. The viability and sterility of the cells was also tested to show that potency observed reflects the activity of live cells, and that cell activation was due to the hypoosmotic-shock step rather than contamination. The results are presented in Tables 1 -3.
The analysis of the three FB batches revealed that the presently disclosed methods achieve at least the unexpected results of stable and sustained production and release of IL-8 when stored at 2-8° C for 7 days post-production.
TABLE 1
Activation Analysis of Batch 4
Time
FBC FP 27RT 27RF 3D 4D 5D 6D 7D point
Viability NA 99 96 94 94 93 92 96 90
CDl lb 32 271 249 262 354 276 283 296 181
CD62L 409 41 18 21 8 5 4 J
CD68 4 14 12 1 1 1 1 10 12 13 13
HLA-DR 98 243 484 166 161 178 173 173 172
IL-8
36 732 2584 987 1242 1297 1603 1308 NA RPMI
IL-8
1 1 1 1647 4443 2510 1752 2457 2843 2433 4050 Serum
IL-8
9 4685 14698 3849 4730 4589 61 16 7443 6757 Content
TABLE 2
Activation Analysis of Batch 5
Time
FBC FP 27RT 27RF 3D 4D 5D 6D 7D point
Viability NA 98 98 98 97 95 99 90 90
CDl lb 29 316 366 300 254 292 250 245 243
CD62L 348 38 j 20 6 4 2 2 1
CD68 6 1 1 9 1 1 1 1 10 10 9 10
HLA-DR 78 205 332 154 145 165 193 165 157
IL-8
58 932 4504 1352 1262 1400 1061 1059 1057 RPMI
IL-8
99 2725 7466 2942 4534 391 1 2804 2294 Serum
IL-8
5 3761 29700 4589 6028 6249 5705 5376 5641 Content
TABLE 3
Activation Analysis of Batch 6
Time
FBC FP 27RT 27RF 3D 4D 5D 6D 7D point
Viability NA 99 99 98 96 94 93 94 86
CDl lb 5 263 242 281 273 251 288 272 182
CD62L 593 95 31 48 34 9 10 1 1 2
CD68 4 14 13 1 1 1 1 14 14 15 15
HLA-DR 98 227 376 151 136 156 195 156 202
IL-8
76 552 4048 789 725 791 901 928 975 RPMI
IL-8
1 13 2859 10328 3402 2236 2252 2550 2097 1951 Serum
IL-8
j 1695 15228 2145 2349 3312 2564 2752 3261 Content
Mean and standard deviations for the three batches are shown in the following tables:
As shown in FIG. 5, the fluorescent intensity of all three batches (i.e., Batches 4, 5, and 6) stained with anti-CD l l b antibody were at least 30% higher at all time points as compared to the intensity of the Fresh Buffy Coat (FBC) stained with anti-CDl l b.
As shown in FIG. 6, the IL-8 concentrations for these three batches were at least 30% higher at all time points as compared to the IL-8 concentration in the Fresh Buffy Coat (FBC).
As shown in FIG. 7, the fluorescent intensity of all three batches stained with ant i-CD62L antibody were at least 30% lower at all time points as compared to the intensity of the Fresh Buffy Coat (FBC) stained with anti-CD62L.
As shown in FIG. 8, the fluorescent intensity of all three batches stained with anti-CD68 antibody were at least 30% higher at all time points as compared to the intensity of the Fresh Buf
As shown in FIG. 9, the fluorescent intensity of all three batches stained with anti-HLA-DR antibody were at least 30% higher at all time points as compared to the intensity of the Fresh Buffy Coat (FBC) stained with anti-HLA-DR antibody.
These analyses reveal that storage of the ALCs at cold temperatures maintained the viability of the cells, and the potency of the ALC for a longer period compared to ALCs stored at room temperature.
Example 7: Analysis of Activated Leukocytes Stored at Room Temperature
Activated leukocytes made according to the methods disclosed herein were tested following activation (T = 0), and after 1 , 3, and 7 days storage at room temperature. The following data were obtained:
As shown in FIG. 10, significant degradation was observed in WBC concentration over the storage period of time. The degradation line exceeded 2.0xl 06 cells/ml after 2 days storage at RT.
As shown in FIG. 1 1 , a significant increase was observed in lymphocyte percentage over the storage period of time. The percentage exceeded 43% after 2 days storage at RT.
Claims
1. A method for the storing an activated leukocyte composition comprising:
providing the activated leukocyte composition; and
maintaining the activated leukocyte composition at a temperature ranging from above 0° C to below about 10° C.
2. The method of claim 1 , wherein the temperature ranges from about 2° C to about 8° C.
3. The method of claim 2, wherein the temperature ranges from about 4° C to about 6° C.
4. The method of claim 3, wherein the temperature is about 5° C.
5. The method of claim 2, wherein the activated leukocyte composition is maintained at a temperature ranging from 2° C to about 8° C for about 1 , 2, 3, 4, 5, 6, or 7 days.
6. The method of claim 3, wherein the activated leukocyte composition is maintained at a temperature ranging from about 4° C to about 6° C for about 1 , 2, 3, 4, 5, 6, or 7 days.
7. The method of claim 4, wherein the activated leukocyte composition is maintained at a temperature of about 5° C for about 1 , 2, 3, 4, 5, 6, or 7 days.
8. An activated leukocyte composition stored according to the method of claim 1.
9. The activated leukocyte composition of claim 8, wherein the composition comprises serum.
10. The activated leukocyte composition of claim 8, wherein at least 85% of cells in the activated leukocyte composition remain viable after seven days of storage.
1 1. The activated leukocyte composition of claim 10, wherein at least 90% of cells in the activated leukocyte composition remain viable after seven days of storage.
12. A method for prolonging the activity of leukocytes in an activated leukocyte composition comprising:
providing the activated leukocyte composition; and
maintaining the activated leukocyte composition at a temperature ranging from above 0° C to below about 10° C.
13. The method of claim 12, wherein the temperature ranges from about 2° C to about 8° C.
14. The method of claim 13, wherein the temperature ranges from about 4° C to about 6° C.
15. The method of claim 14, wherein the temperature is about 5° C.
16. The method of claim 12, wherein the activated leukocyte composition is maintained at a temperature ranging from 2° C to about 8° C for about 1 , 2, 3, 4, 5, 6, or 7 days.
17. The method of claim 16, wherein the activated leukocyte composition is maintained at a temperature ranging from 4° C to about 6° C for about 1 , 2, 3, 4, 5, 6, or 7 days.
18. The method of claim 17, wherein the activated leukocyte composition is maintained at a temperature of about 5° C for about 1 , 2, 3, 4, 5, 6, or 7 days.
19. An activated leukocyte composition comprising leukocytes having prolonged activity made according to the method of claim 12.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462078165P | 2014-11-11 | 2014-11-11 | |
US62/078,165 | 2014-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016075542A1 true WO2016075542A1 (en) | 2016-05-19 |
Family
ID=55024172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/002285 WO2016075542A1 (en) | 2014-11-11 | 2015-11-10 | Methods for extended storage of activated leukocyte compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016075542A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012151266A1 (en) * | 2011-05-03 | 2012-11-08 | Michael Har-Noy | Methods for handling biological drugs containing living cells |
US20130071465A1 (en) | 2009-03-05 | 2013-03-21 | Macrocure Ltd. | Activated leukocyte composition and uses for wound healing |
WO2013136182A1 (en) * | 2012-03-15 | 2013-09-19 | Macrocure, Ltd. | Activated immunostimulatory cell composition and uses thereof |
-
2015
- 2015-11-10 WO PCT/IB2015/002285 patent/WO2016075542A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130071465A1 (en) | 2009-03-05 | 2013-03-21 | Macrocure Ltd. | Activated leukocyte composition and uses for wound healing |
US8574902B2 (en) | 2009-03-05 | 2013-11-05 | Macrocure Ltd. | Activated leukocyte composition and uses for wound healing |
US20140004091A1 (en) | 2009-03-05 | 2014-01-02 | Macrocure Ltd. | Activated Leukocyte Composition and Uses For Wound Healing |
WO2012151266A1 (en) * | 2011-05-03 | 2012-11-08 | Michael Har-Noy | Methods for handling biological drugs containing living cells |
WO2013136182A1 (en) * | 2012-03-15 | 2013-09-19 | Macrocure, Ltd. | Activated immunostimulatory cell composition and uses thereof |
Non-Patent Citations (1)
Title |
---|
DUMFARTH ET AL., ANN. THORAC. SURG, vol. 86, 2008, pages 1909 - 1913 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6892485B2 (en) | Preparation of thrombin serum, its utilization and its preparation equipment | |
AU2010220132B2 (en) | Activated leukocyte composition | |
US9439950B2 (en) | Activated leukocyte conditioned supernatant and uses for wound healing | |
US20150352151A1 (en) | Activated leukocyte composition and uses for wound healing | |
WO2016075542A1 (en) | Methods for extended storage of activated leukocyte compositions | |
RU2805189C1 (en) | Method of autodermoplasty | |
AU2013203115B2 (en) | Process,tube and device for the preparation of wound healant composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15816515 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15816515 Country of ref document: EP Kind code of ref document: A1 |